Literature DB >> 23801279

Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence.

Evgeny N Suspitsin1, Aniruddh Kashyap, Kseniya V Shelekhova, Anna P Sokolenko, Ekatherina Sh Kuligina, Aglaya G Iyevleva, Alexandr V Kornilov, Volker Ehemann, Grigoriy A Yanus, Svetlana N Aleksakhina, Elena V Preobrazhenskaya, Olga A Zaitseva, Olga S Yatsuk, Valeriy F Klimashevsky, Alexandr V Togo, Evgeny N Imyanitov.   

Abstract

Angiogenesis plays an important role in cancer progression and involves activation of multiple signaling cascades. This study investigated the relationships between microvessel density, expression of VEGF and VEGFR1 (FLT1), and gastric cancer (GC) recurrence. Twenty-nine surgically treated GC cases with similar initial clinical presentation were selected for the study; 11 of these cases recurred within 3 years, while the remaining 18 did not. Microvessel density correlated with VEGF mRNA content, but neither of these parameters was associated with the disease outcome. When tumors were ranked according to the level of expression of angiogenic molecules, 9 out of 10 cases with the highest VEGFR1 expression belonged to the recurrence group, while none of the 10 GC with the lowest content of VEGFR1 mRNA had the disease relapse (p = 0.000). VEGFR1 expression did not show even a trend to correlation with the level of cancer tissue vascularization. Immunofluorescent staining by anti-VEGFR1 antibody revealed VEGFR1 expression in tumor cells but not in other cell types. Our data provide indirect support to the evidence for a non-angiogenic contribution of VEGFR1 in cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801279     DOI: 10.1007/s12032-013-0644-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer.

Authors:  M Moehler; A Mueller; J T Hartmann; M P Ebert; S E Al-Batran; P Reimer; M Weihrauch; F Lordick; T Trarbach; S Biesterfeld; M Kabisch; D Wachtlin; P R Galle
Journal:  Eur J Cancer       Date:  2011-05-09       Impact factor: 9.162

3.  Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells.

Authors:  Zeng Yong Yi; Liu Jing Feng; Zhang Xiang; Huang Yao
Journal:  J Invest Surg       Date:  2011       Impact factor: 2.533

4.  VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.

Authors:  Natasha Y Frank; Tobias Schatton; Soo Kim; Qian Zhan; Brian J Wilson; Jie Ma; Karim R Saab; Veronika Osherov; Hans R Widlund; Martin Gasser; Ana-Maria Waaga-Gasser; Thomas S Kupper; George F Murphy; Markus H Frank
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

5.  The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.

Authors:  Yan Wu; Andrea T Hooper; Zhaojing Zhong; Larry Witte; Peter Bohlen; Shahin Rafii; Daniel J Hicklin
Journal:  Int J Cancer       Date:  2006-10-01       Impact factor: 7.396

Review 6.  Evaluation of microvascular density in tumors: pro and contra.

Authors:  Beatrice Nico; Vincenzo Benagiano; Domenica Mangieri; Nicola Maruotti; Angelo Vacca; Domenico Ribatti
Journal:  Histol Histopathol       Date:  2008-05       Impact factor: 2.303

7.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

8.  Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase.

Authors:  Shunichi Tsujitani; Hiroaki Saito; Yoshihiko Maeta; Kenichi Yamaguchi; Shigeru Tatebe; Akira Kondo; Nobuaki Kaibara
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

9.  Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.

Authors:  Yanislav Kolev; Hiroyuki Uetake; Satoru Iida; Toshiaki Ishikawa; Tatsuyuki Kawano; Kenichi Sugihara
Journal:  Ann Surg Oncol       Date:  2007-08-09       Impact factor: 5.344

10.  Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.

Authors:  Yoshinori Hirashima; Yasuhide Yamada; Junichi Matsubara; Daisuke Takahari; Natsuko Okita; Atsuo Takashima; Ken Kato; Tetsuya Hamaguchi; Kuniaki Shirao; Yasuhiro Shimada; Hirokazu Taniguchi; Tadakazu Shimoda
Journal:  Cancer Sci       Date:  2009-02       Impact factor: 6.716

View more
  4 in total

1.  125I-F56 Peptide as Radioanalysis Agent Targeting VEGFR1 in Mice Xenografted with Human Gastric Tumor.

Authors:  Hua Zhu; Chuanke Zhao; Fei Liu; Lixin Wang; Junnan Feng; Chengchao Shou; Zhi Yang
Journal:  ACS Med Chem Lett       Date:  2017-01-20       Impact factor: 4.345

2.  Expression of vascular endothelial growth factor and basic fibroblast growth factor in extramammary Paget disease.

Authors:  Xiaoyun Xu; Ning Shao; Di Qiao; Zengjun Wang; Ningjing Song; Ninghong Song
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  Emerging molecular basis of hematogenous metastasis in gastric cancer.

Authors:  Jing Zhong; Yan Chen; Liang-Jing Wang
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

4.  Dapper homolog 1 alpha suppresses metastasis ability of gastric cancer through inhibiting planar cell polarity pathway.

Authors:  Yuegeng Liu; Jingwan Zhang; Weifang Yu; Xiaoming Zhang; Guiqi Wang; Zengren Zhao
Journal:  Oncotarget       Date:  2016-12-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.